Fulgent Genetics Inc Stock News

Strong earnings sent both of these healthcare stocks higher after hours on Thursday.

Shares of Fulgent Genetics (NASDAQ:FLGT) moved higher by 24.0% in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 15400.00% year over year to $

Fourth Quarter 2020 Results:

These stocks made investors a lot of money in 2020. Which one will be the better choice this year?

Massive growth from COVID testing is hiding an excellent business.

All three of these stocks have had incredible spikes because of COVID-19. One stock, however, is a safer and stronger long-term investment.

Here's why Fulgent stock is running so high.

We expect strong demand for Fulgent Genetics' (FLGT) end-to-end tests for COVID-19 to have continued through the fourth quarter.

FULGENT GENETIC (FLGT) closed at $110.38 in the latest trading session, marking a +1.55% move from the prior day.

Is (FLGT) Outperforming Other Medical Stocks This Year?

Top Ranked Momentum Stocks to Buy for February 24th

It's a volatile stock right now. But the future for genomic testing looks bright.

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

It's possible that some stocks could fly higher with the policy change being considered by the Biden administration.

Here are five important factors to consider when you're looking for the next big stock winners. The post Stock Winners: 5 Factors That Can Give You 10X Potential appeared first on InvestorPlace.